Related topics: Globalisation, Consolidation, Clinical evolution, Clinical Development, Phase I-II, Phase III-IV, Regulatory affairs
US CRO Clinilabs hopes its new link up with Chinese counterpart H&J CRO International will allow it to “manage early phase and specialty studies in the US, while offering our clients the cost efficiencies found in the Asian labour market.”
The partnership, announced late yesterday, will combine New York based Clinilabs’ Phase I and II trial services offering with H&J clinical research and regulatory affairs knowhow in China and Asia as a whole.
H&J, which is also headquartered in New York but has two branch offices in Shanghai and Beijing, plans to expand it presence in the US contract research market through the Clinilabs deal.
Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions